Skip to main content
TipRanks
Go Ultimate75% OFF

Tandem Diabetes Care (0M0F) AI Stock Analysis

6 Followers
GB:0M0F

Tandem Diabetes Care

(LSE:0M0F)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Recurring Supply RevenueTandem’s installed-pump model creates an ongoing consumables stream because users need disposable supplies for daily insulin delivery. This recurring demand can improve customer lifetime value, make revenue more durable than hardware sales alone, and support cross-selling as the installed base grows.
Negative Factors
High LeverageThe sharp increase in leverage and thinner equity base reduces financial flexibility and raises sensitivity to operating volatility. Higher debt can constrain capital allocation, increase the importance of sustained earnings improvement, and make execution more consequential if growth or margins weaken.

Tandem Diabetes Care (0M0F) vs. iShares MSCI United Kingdom ETF (EWC)

-40%-20%0%20%40%60%GB:0M0F+4.41%EWC+21.04%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$1.40B
Dividend Yield
―
Average Volume (3M)
727
Price to Earnings (P/E)
-27.9
Beta (1Y)
1.28
Revenue Growth
6.73%
EPS Growth
76.54%
Country
UK
Employees
2,500
Sector
Healthcare
Sector Strength
51
Industry
Medical - Devices

Tandem Diabetes Care Business Overview & Revenue Model

Company Description

Tandem Diabetes Care, Inc., a medical technology firm, specializes in creating, developing, and marketing solutions for individuals globally who manage insulin-dependent diabetes. At the core of its offerings is the t:slim X2 insulin delivery system,...

Tandem Diabetes Care Earnings Call Summary

Earnings Call Date:Nov 05, 2026(Q3-2026)|% Change Since:10.51%|Next Earnings Date:Feb 24, 2027
Earnings Call SentimentPositive

The call was broadly positive, supported by record third-quarter revenue and pump shipments, improving U.S. customer starts, international growth, gross-margin expansion, positive adjusted EBITDA for the fifth consecutive quarter, reaffirmed 2026 guidance and progress across the Mobi Tubeless and fully closed-loop pipelines. The main cautions were slower-than-expected pharmacy adoption, related revenue headwinds extending into 2027, infusion-set supply constraints, direct-market transition costs and the unresolved C-peptide requirement for type 2 access.

Positive Updates

Record Third-Quarter Revenue and Pump Shipments
Worldwide revenue grew 14% year-over-year to $284 million, while pump shipments increased 12% to approximately 33,000 pumps. Both sales and pump shipments reached third-quarter records.

Negative Updates

Pharmacy Adoption Was Slower Than Initially Expected
Pharmacy adoption is scaling, but the pace of transition was more gradual than initially anticipated because of the time required to establish prescription workflows and change behaviors among teams, health care providers and customers. Pharmacy represented approximately 12% of pump shipments and 7% of the ordering installed base in the quarter.

Company Guidance

For 2026, worldwide sales are expected to be in the range of $1.065 billion to $1.085 billion, including U.S. sales in the range of $730 million to $745 million and international sales in the range of $335 million to $340 million; gross margins are expected in the range of 56% to 57% and adjusted EBITDA margin of 5% to 6% of annual sales. In the fourth quarter, Tandem anticipates shipping approximately 15% to 20% of pumps and 8% to 10% of installed base supplies through pharmacy, representing nearly 15% of U.S. sales; for the year, PayGo pumps will be more like 10% to 12% and pharmacy as a percent of sales will probably average something more in the low teens, like also 10% to 12%. For 2027, a mid- to high-single digit increase year-over-year is a fair starting point, Mobi Tubeless is expected to reach full commercial availability in the first half of 2027, and direct operations are expected to expand to approximately half of the installed base by the end of next year.

Tandem Diabetes Care Risk Analysis

Tandem Diabetes Care disclosed 63 risk factors in its most recent earnings report. Tandem Diabetes Care reported the most risks in the "Finance & Corporate" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

0 New Risks

Tandem Diabetes Care Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

GB:0M0F against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
MDTMDT81Outperform$131.58B25.1510.60%2.78%9.77%12.28%
DXCMDXCM73Outperform$31.08B32.1736.50%―13.03%40.88%
PODDPODD73Outperform$10.58B24.7929.48%―26.46%75.56%
ABTABT67Neutral$187.95B40.199.11%2.32%10.00%-66.06%
BBNXBBNX60Neutral$892.71M-8.78-27.33%―43.69%-3.00%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%

* Healthcare Sector Average

Performance Comparison

-50%0%50%GB:0M0FABTDXCMPODDMDTBBNXDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
GB:0M0F and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
GB:0M0FTandem Diabetes Care20.020.894.66%
ABTAbbott Laboratories108.52-18.36-14.47%
DXCMDexcom83.3324.8442.47%
PODDInsulet152.48-175.54-53.52%
MDTMedtronic102.869.6710.38%
BBNXBeta Bionics, Inc.16.42-10.74-39.54%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.